A phase I trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies

Wuthrick, Evan; Werner‐Wasik, Maria; Lin, Alexander; Axelrod, R. A.; Pereira-Rico, A.; Murphy, H.; Machtay, Mitchell; Dicker, Adam P.

doi:10.1200/jco.2008.26.15_suppl.2053

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, sunitinib is being investigated in combination with radiation therapy for patients with primary and metastatic malignancies of the central nervous system. 30 In conclusion, sunitinib therapy in metastatic brain disease from RCC is an additional treatment option in patients whose previous treatment armamentarium was severely limited. However, use of sunitinib in metastatic RCC patients with brain metastases may require future prospective randomized trials.…”

Section: Discussionmentioning

confidence: 99%

Sunitinib in metastatic renal cell carcinoma patients with brain metastases

Gore

Subramanian

Porta

et al. 2010

Cancer

135

View full text Add to dashboard Cite

BACKGROUND:In a broad patient population with metastatic renal cell carcinoma (RCC), enrolled in an open-label, expanded access program (EAP), the safety profile of sunitinib was manageable, and efficacy results were encouraging. Here, the authors report results for patients with baseline brain metastases participating in this global EAP. METHODS: Previously treated and treatment-naive metastatic RCC patients !18 years received sunitinib 50 mg orally, once daily, on Schedule 4/2. Safety was assessed regularly, tumor measurements done per local practice, and survival data collected where possible. Analyses were done in the modified intention-to-treat (ITT) population, consisting of all patients who received !1 dose of sunitinib. RESULTS: As of December 2007, 4564 patients had enrolled in 52 countries. Of these enrollees, 4371 were included in the modified ITT population, of whom 321 (7%) had baseline brain metastases and had received a median of 3 treatment cycles (range 1-25). Reasons for their discontinuation included lack of efficacy (32%) and adverse events (8%). The most common grade 3-4 treatment-related adverse events were fatigue and asthenia (both 7%), thrombocytopenia (6%), and neutropenia (5%), the incidence of which were comparable to that for the overall EAP population. Of 213 evaluable patients, 26 (12%) had an objective response. Median progression-free survival and overall survival were 5.6 months (95% CI, 5.2-6.1) and 9.2 months (95% CI, 7.8-10.9), respectively. CONCLUSIONS: In patients with brain metastases from RCC, the safety profile of sunitinib was comparable to that in the general metastatic RCC population, and sunitinib showed evidence of antitumor activity. Cancer 2011;117:501-9.

show abstract

Section: Discussionmentioning

confidence: 99%

Sunitinib in metastatic renal cell carcinoma patients with brain metastases

Gore

Subramanian

Porta

et al. 2010

Cancer

135

View full text Add to dashboard Cite

show abstract

Molecular Advances of Brain Tumors in Radiation Oncology

Noda

El‐Jawahri

Patel

et al. 2009

Seminars in Radiation Oncology

View full text Add to dashboard Cite

Antiangiogenic therapy for glioblastoma multiforme: Possibilities and promises

Borisov,

Sakaeva,

Borisov

et al. 2011

Russian Journal of Oncology

View full text Add to dashboard Cite

The review provides information on the role of antiangiogenic therapy for glioblastoma multiforme. Bevacizumab in combination with irinotecan allows tumor growth to be controlled in the majority of patients. Thalidomide may be an alternative to bevacizumab although its efficacy requires further investigations and confirmation. The activity of tyrosine kinase VEGRF inhibitors in monotherapy for glioblastoma is minimal; in this connection their combinations with standard chemoradiotherapy is being studied. Certain hopes are pinned on the new group of drugs - integrin receptor inhibitors.

show abstract

A phase I trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies

Cited by 3 publications

References 0 publications

Sunitinib in metastatic renal cell carcinoma patients with brain metastases

Sunitinib in metastatic renal cell carcinoma patients with brain metastases

Molecular Advances of Brain Tumors in Radiation Oncology

Antiangiogenic therapy for glioblastoma multiforme: Possibilities and promises

Contact Info

Product

Resources

About